NCT06608147 MOLyF : Bone Marrow and Follicular Lymphoma
| NCT ID | NCT06608147 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rennes University Hospital |
| Condition | Lymphoma, Follicular |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-12-04 |
| Primary Completion | 2034-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-12-04 with a primary completion date of 2034-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective single-center study designed to assess potential differences in cell composition between bone marrows of patients with follicular lymphoma and those from control subjects. Follicular lymphoma is the most common indolent lymphoma. It is characterised by systematic relapses and bone marrow dissemination in 70% of patients at the time of diagnosis. Although relapses are thought to be related to refractory tumour cells nested in a supportive microenvironment in the bone marrow, the mechanisms involved are poorly understood. To study the specificities of the bone marrow of patients with follicular lymphoma, It is necessary to compare them with control samples. This study takes advantage of surgeries involving sternotomies to recover lost bone marrow and establish a bone marrow bank of patients without hematological disease. This bank will be used to set up control cohorts for other clinical trials involving patients with follicular lymphoma.
Eligibility Criteria
Inclusion Criteria: * Major patient * Patient hospitalized in the thoracic, cardiac and vascular surgery department for surgery involving a sternotomy * Patient with free, informed, written consent * Patient covered by a health insurance scheme Exclusion Criteria: * History of haematological malignancy or haemogram disturbance * Immunomodulating treatment: immunosuppressants, corticoids, antineoplastics * Persons covered by articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the French Public Health Code (e.g. minors, protected adults, etc.)\].
Contact & Investigator
Juliette Ferrant, MD
STUDY CHAIR
Rennes University Hospital
Frequently Asked Questions
Who can join the NCT06608147 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphoma, Follicular. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06608147 currently recruiting?
Yes, NCT06608147 is actively recruiting participants. Contact the research team at juliette.ferrant@chu-rennes.fr for enrollment information.
Where is the NCT06608147 trial being conducted?
This trial is being conducted at Rennes, France.
Who is sponsoring the NCT06608147 clinical trial?
NCT06608147 is sponsored by Rennes University Hospital. The principal investigator is Juliette Ferrant, MD at Rennes University Hospital. The trial plans to enroll 200 participants.